No Data
No Data
Imugene Receives Substantial Capital Injection; Extends Cash Runway to End of 2025 in Support of Ongoing Trials
Imugene to Raise AU$46 Million in Convertible Notes, Warrants Issue
Imugene to Receive A$11 Million R&D Tax Refund for FY23 | ASX:IMU, OTC:IUGNF
6 ASX Shares Down 50%+ in 2024. Are They Cheap?
Imugene Doses First Patient in Intratumoral Injection Group of Phase 1 Cancer Trial
Five at Five AU: ASX to End Week on a High Note | ASX:IMU, OTC:IUGNF
151479178 : What are you talking about